jxfzsy
- The US FDA granted an additional indication for Eli Lilly’s (LLY) Jaypirca (pirtobrutinib) as a first-line treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion.
- The non-covalent BTK inhibitor was approved in